Urinary retention is the inability to empty the bladder. With chronic urinary retention, you may be able to urinate, but you have trouble starting a stream or emptying your bladder completely. You may urinate frequently; you may feel an urgent need to urinate but have little success when you get to the toilet; or you may feel you still have to go after you’ve finished urinating. With acute urinary retention, you can’t urinate at all, even though you have a full bladder. Acute urinary retention is a medical emergency requiring prompt action. Chronic urinary retention may not seem life threatening, but it can lead to serious problems and should also receive attention from a health professional.
A first case of acute myelitis following infection with Zika virus has been reported for the first time by a research team from Inserm Unit 1127 Brain and Spinal Cord Institute (Inserm/CNRS/Sorbonne University) and neurologists at Pointe-à-Pitre University Hospital and the University of the Antilles.
While Botulinum toxin A (BTX-A), known to the public as Botox, is commonly associated with smoothing wrinkles for a more youthful appearance, three studies presented at the 110th Annual Scientific Meeting of the American Urological Association are proving BTX-A to be more than just a cosmetic solution.
Antimuscarinics “could and should” be used in the pharmacological treatment of men with lower urinary tract symptoms caused by benign prostatic hyperplasia or bladder outlet obstruction, say the authors of a meta-analysis published in Urology.
In a new phase III trial mirabegron, a β3-adrenoceptor agonist, given once daily for 12 weeks, reduced the frequency of incontinence episodes and number of daily urinations, and improved urgency and nocturia in adults with overactive bladder compared to those in a placebo group.
Treating benign prostate obstruction with thulium vapoenucleation of the prostate is well-tolerated and effective and leads to a low incidence of perioperative complications, according to recent study findings.
A new interventional radiology treatment, prostatic artery embolization, may bring hope to men with debilitating symptoms caused by an enlarged prostate, say the group of researchers who pioneered its use.
Men who experience a sudden inability to pass urine because of a non-cancerous enlarged prostate are hospitalised and treated differently depending on where they live, according to an international study published online by the urology journal BJUI.
Valeant Pharmaceuticals International, Inc. and GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) has approved Potiga Tablets, a potassium channel opener, as adjunctive treatment of partial-onset seizures in patients aged 18 years and older.
GlaxoSmithKline (GSK) today announced that the Company has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for the supplemental New Drug Application (sNDA) for Avodart® (dutasteride) for reducing the risk of prostate cancer in men at increased risk for the disease, defined as those who have had a prior negative biopsy due to clinical concern and have an elevated serum prostate-specific antigen (PSA).
Recordati and Nymox Pharmaceutical Corporation announced today the signing of a European licensing agreement for the development and commercialization of NX-1207, Nymox's Phase III investigational drug currently in clinical development in the U.S. for the treatment of benign prostatic hyperplasia (BPH).
Nymox Pharmaceutical Corporation announced today that it has been awarded a grant of $244,479.25 from the U.S Government under the Qualifying Therapeutic Discovery Project for its ongoing Phase III clinical trial program for NX-1207 for the treatment of benign prostatic hyperplasia (BPH). The grant was the maximum allowable for an individual development program.
Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 pivotal trials for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH).
Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The Safety Monitoring Committee meeting of July 22, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 was favorable and indicated no significant safety concerns for the trials to date. Patient recruitment and trial activities for pivotal U.S. studies NX02-0017 and NX02-0018 are proceeding at over 70 well-known urology investigative sites throughout the U.S.
Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia. The most recent Safety Monitoring Committee meeting of April 30, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 indicated no significant safety concerns for the trials to date.
Like any successful team effort, the best qualities of two drugs commonly prescribed for enlarged prostate yielded better results than either of the medicines alone, according to a new study from UT Southwestern Medical Center.
ProtekMed has launched the Tru-flo(TM) urinary catheter valve, an innovative and economical alternative to the standard tube and bag system prescribed by most urologists today.
AbbeyMoor Medical Inc. announced today they have been granted a Category I CPT code by the American Medical Association (AMA) for The Spanner(TM) temporary prostatic stent insertion procedure. This important action, effective in January 2010, upgrades The Spanner from a Category III emerging technology procedure code to a Category I procedure code for established procedures.
Children with a history of consuming melamine-contaminated milk powder are at an increased risk of developing kidney stones and other urological complications.
Nymox Pharmaceutical Corporation has announced that the Company's latest multi-center U.S. study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia (BPH), is nearing completion.
As many as one in four men admitted to hospital with acute urinary retention will die within a year, finds a study published on bmj.com.